{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:21:20Z","timestamp":1793996480540,"version":"4.8.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008457","name":"University of Virginia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008457","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bbadis.2024.167648","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T02:38:07Z","timestamp":1735526287000},"page":"167648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Biological agents as attractive targets for inflammatory bowel disease therapeutics"],"prefix":"10.1016","volume":"1871","author":[{"given":"Jia-Chen","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ting","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2024.167648_bb0005","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn's disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2024.167648_bb0010","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/17474124.2019.1574569","article-title":"Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis","volume":"13","author":"Greuter","year":"2019","journal-title":"Expert Rev Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/bega.2001.0267","article-title":"Inflammatory bowel disease","volume":"16","author":"Gurudu","year":"2002","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114893","article-title":"The gut microbes in inflammatory bowel disease: future novel target option for pharmacotherapy","volume":"165","author":"Yuan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbadis.2024.167648_bb0030","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2024.167648_bb0035","article-title":"Histological hallmarks of mucosal healing in inflammatory bowel diseases in the era of monoclonal antibodies therapy: new insights and perspectives","volume":"11","author":"Cazzato","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.bbadis.2024.167648_bb0040","doi-asserted-by":"crossref","first-page":"604","DOI":"10.5009\/gnl19019","article-title":"Perspectives on current and novel treatments for inflammatory bowel disease","volume":"13","author":"Na","year":"2019","journal-title":"Gut Liver"},{"key":"10.1016\/j.bbadis.2024.167648_bb0045","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/apt.13995","article-title":"Review article: moving towards common therapeutic goals in Crohn\u2019s disease and rheumatoid arthritis","volume":"45","author":"Allen","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2024.167648_bb0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4110\/in.2017.17.1.25","article-title":"Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies","volume":"17","author":"Kim","year":"2017","journal-title":"Immune Netw."},{"key":"10.1016\/j.bbadis.2024.167648_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.892790","article-title":"Traditional Chinese medicine and natural products: potential approaches for inflammatory bowel disease","volume":"13","author":"Yuan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0060","doi-asserted-by":"crossref","first-page":"G716","DOI":"10.1152\/ajpgi.00472.2010","article-title":"Immune and nonimmune components orchestrate the pathogenesis of inflammatory bowel disease","volume":"300","author":"Danese","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous Vedolizumab in patients with moderately to severely active Crohn\u2019s disease: results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.bbadis.2024.167648_bb0070","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40265-020-01460-3","article-title":"Vedolizumab and Extraintestinal manifestations in inflammatory bowel disease","volume":"81","author":"Hanzel","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bbadis.2024.167648_bb0075","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor alpha real-world outcomes in biologic-naive inflammatory bowel disease patients: results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.bbadis.2024.167648_bb0080","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.3748\/wjg.v25.i30.4125","article-title":"Intestinal enteroids\/organoids: a novel platform for drug discovery in inflammatory bowel diseases","volume":"25","author":"Yoo","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ajg.2010.392","article-title":"The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?","volume":"106","author":"D'Haens","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0090","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2174\/1389450117666160527142719","article-title":"Biologic therapies in ulcerative colitis: primi inter pares?","volume":"19","author":"Allocca","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bbadis.2024.167648_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8101646","article-title":"Adalimumab therapy improves intestinal dysbiosis in Crohn\u2019s disease","volume":"8","author":"Ribaldone","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0100","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/00365521.2020.1722738","article-title":"Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease","volume":"55","author":"Hossain","year":"2020","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.bbadis.2024.167648_bb0110","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/jgh.14624","article-title":"Long-term outcomes of patients with Crohn\u2019s disease who received infliximab or adalimumab as the first-line biologics","volume":"34","author":"Inokuchi","year":"2019","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0115","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0120","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2024.167648_bb0125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2024.167648_bb0130","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2024.167648_bb0135","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/03007995.2019.1579557","article-title":"Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis","volume":"35","author":"Taxonera","year":"2019","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.bbadis.2024.167648_bb0140","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.bbadis.2024.167648_bb0145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MEG.0000000000000763","article-title":"Short article: the effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients","volume":"29","author":"Taks","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0150","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/00365521.2019.1582693","article-title":"Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy","volume":"54","author":"Bots","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0155","first-page":"74","article-title":"Efficacy and tolerability of certolizumab pegol in Crohn\u2019s disease in clinical practice","volume":"90","author":"Knyazev","year":"2018","journal-title":"Ter. Arkh."},{"key":"10.1016\/j.bbadis.2024.167648_bb0160","first-page":"1333","article-title":"Meta-analysis: serious adverse events in Crohn's disease patients treated with TNF-alpha inhibitors","volume":"60","author":"Zhang","year":"2013","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.bbadis.2024.167648_bb0165","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1093\/ecco-jcc\/jjx107","article-title":"Targeting S1P in inflammatory bowel disease: new avenues for modulating intestinal leukocyte migration","volume":"12","author":"Danese","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.bbadis.2024.167648_bb0170","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ajhg.2009.01.026","article-title":"Diverse genome-wide association studies associate the IL12\/IL23 pathway with Crohn disease","volume":"84","author":"Wang","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2024.167648_bb0175","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/gut.2006.115402","article-title":"The IL23 axis plays a key role in the pathogenesis of IBD","volume":"56","author":"McGovern","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2024.167648_bb0180","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0185","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2147\/JIR.S165330","article-title":"Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives","volume":"11","author":"Rawla","year":"2018","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.bbadis.2024.167648_bb0190","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab in Crohn's Disease Study, Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2024.167648_bb0195","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1756283X10374216","article-title":"Review of the safety and efficacy of ustekinumab","volume":"3","author":"Scherl","year":"2010","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0205","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0210","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0215","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ecco-jcc\/jjz110","article-title":"IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn\u2019s disease","volume":"14","author":"Hanauer","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.bbadis.2024.167648_bb0220","first-page":"571","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) errata","volume":"19","author":"Papp","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0225","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.cgh.2018.01.030","article-title":"Efficacy of medical therapies for fistulizing Crohn\u2019s disease: systematic review and meta-analysis","volume":"16","author":"Lee","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0230","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/ibd\/izy302","article-title":"Ustekinumab is effective for the treatment of Crohn\u2019s disease of the pouch in a multicenter cohort","volume":"25","author":"Weaver","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.bbadis.2024.167648_bb0235","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2024.167648_bb0240","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.gastro.2017.03.049","article-title":"Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn\u2019s disease: a phase 2a study","volume":"153","author":"Sands","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2024.167648_bb0245","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.gastro.2019.08.043","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2024.167648_bb0250","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cgh.2020.09.028","article-title":"Efficacy and safety of continued treatment with mirikizumab in a phase 2 trial of patients with ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0255","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn\u2019s disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2024.167648_bb0260","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1136\/gutjnl-2018-317977","article-title":"Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances","volume":"68","author":"Zundler","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2024.167648_bb0265","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.2174\/13894501113149990158","article-title":"Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease","volume":"14","author":"Bamias","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bbadis.2024.167648_bb0270","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/apt.12639","article-title":"Review article: anti-adhesion therapies for inflammatory bowel disease","volume":"39","author":"Lobaton","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2024.167648_bb0275","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/1756283X14558193","article-title":"Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases","volume":"8","author":"Amiot","year":"2015","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0280","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0285","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0290","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1053\/j.gastro.2014.08.044","article-title":"Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases","volume":"147","author":"Danese","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2024.167648_bb0295","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0300","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0305","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/gutjnl-2016-312293","article-title":"Effect of vedolizumab (anti-alpha4beta7-integrin) therapy on histological healing and mucosal gene expression in patients with UC","volume":"67","author":"Arijs","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2024.167648_bb0310","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/ecco-jcc\/jjy019","article-title":"Efficacy of vedolizumab in fistulising Crohn\u2019s disease: exploratory analyses of data from GEMINI 2","volume":"12","author":"Feagan","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.bbadis.2024.167648_bb0315","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists","volume":"15","author":"Feagan","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0320","first-page":"93","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. Reply","volume":"382","author":"Sands","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0325","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10620-018-4971-1","article-title":"Effects of vedolizumab therapy on extraintestinal manifestations in inflammatory bowel disease","volume":"63","author":"Fleisher","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.bbadis.2024.167648_bb0330","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2015.10.041","article-title":"Association between response to etrolizumab and expression of integrin alphaE and granzyme A in colon biopsies of patients with ulcerative colitis","volume":"150","author":"Tew","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2024.167648_bb0335","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1136\/gutjnl-2011-301769","article-title":"A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis","volume":"62","author":"Rutgeerts","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2024.167648_bb0340","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(14)60661-9","article-title":"Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial","volume":"384","author":"Vermeire","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2024.167648_bb0345","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.phrs.2018.11.003","article-title":"Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: a systematic review and indirect comparison","volume":"139","author":"Motaghi","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbadis.2024.167648_bb0350","article-title":"A small molecule, which competes with MAdCAM-1, activates integrin alpha4beta7 and fails to prevent mucosal transmission of SHIV-SF162P3","volume":"12","author":"Arrode-Bruses","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bbadis.2024.167648_bb0355","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(17)30930-3","article-title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"390","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2024.167648_bb0360","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/14712598.2016.1203897","article-title":"Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease","volume":"16","author":"Pouillon","year":"2016","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.bbadis.2024.167648_bb0365","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/gutjnl-2016-312912","article-title":"Next generation of small molecules in inflammatory bowel disease","volume":"66","author":"Olivera","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2024.167648_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus kinase (JAK) activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbadis.2024.167648_bb0375","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13020-022-00633-4","article-title":"Inflammatory bowel disease: an overview of Chinese herbal medicine formula-based treatment","volume":"17","author":"Yuan","year":"2022","journal-title":"Chin. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0380","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0385","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10235660","article-title":"Efficacy, safety and future perspectives of JAK inhibitors in the IBD treatment","volume":"10","author":"Dudek","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0390","doi-asserted-by":"crossref","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","article-title":"New players in the field of immune-mediated diseases, beyond rheumatoid arthritis","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bbadis.2024.167648_bb0395","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41575-021-00574-7","article-title":"Alimentiv translational research, sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease","volume":"19","author":"Verstockt","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0400","doi-asserted-by":"crossref","first-page":"G155","DOI":"10.1152\/ajpgi.00311.2015","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines","volume":"310","author":"Danese","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0405","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0410","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMc1707500","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"377","author":"Dai","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0415","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0420","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Panes","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2024.167648_bb0425","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.bbadis.2024.167648_bb0430","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2024.167648_bb0435","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fphar.2019.00212","article-title":"Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists","volume":"10","author":"Perez-Jeldres","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0440","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0445","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1474-4422(16)30192-2","article-title":"Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"15","author":"Kappos","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0450","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40265-016-0603-2","article-title":"Sphingosine-1-phosphate (S1P) and S1P signaling pathway: therapeutic targets in autoimmunity and inflammation","volume":"76","author":"Tsai","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bbadis.2024.167648_bb0455","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1172\/JCI12821","article-title":"Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease","volume":"108","author":"Monteleone","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2024.167648_bb0460","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","article-title":"Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn\u2019s disease","volume":"372","author":"Monteleone","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0465","first-page":"279","article-title":"A review on chemical-induced inflammatory bowel disease models in rodents, Korean","volume":"18","author":"Randhawa","year":"2014","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0470","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ibd.22957","article-title":"Immune markers and differential signaling networks in ulcerative colitis and Crohn\u2019s disease","volume":"18","author":"Christophi","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.bbadis.2024.167648_bb0475","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/cr.2010.175","article-title":"NF-kappaB in the regulation of epithelial homeostasis and inflammation","volume":"21","author":"Wullaert","year":"2011","journal-title":"Cell Res."},{"key":"10.1016\/j.bbadis.2024.167648_bb0480","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.3748\/wjg.v16.i21.2616","article-title":"Mucosal biomarkers in inflammatory bowel disease: key pathogenic players or disease predictors?","volume":"16","author":"Scaldaferri","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032777","article-title":"Evolution of JAK-STAT pathway components: mechanisms and role in immune system development","volume":"7","author":"Liongue","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2024.167648_bb0490","doi-asserted-by":"crossref","first-page":"316","DOI":"10.4161\/gmic.1.5.13329","article-title":"Enteric pathogens and gut function: role of cytokines and STATs","volume":"1","author":"Shea-Donohue","year":"2010","journal-title":"Gut Microbes"},{"key":"10.1016\/j.bbadis.2024.167648_bb0495","first-page":"C775","article-title":"Inhibition of basal p38 or JNK activity enhances epithelial barrier function through differential modulation of claudin expression","volume":"297","author":"Carrozzino","year":"2009","journal-title":"Am. J. Phys. Cell Phys."},{"key":"10.1016\/j.bbadis.2024.167648_bb0500","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/gutjnl-2012-304241","article-title":"Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling","volume":"63","author":"Pope","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2024.167648_bb0505","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/apt.15719","article-title":"Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn\u2019s disease","volume":"51","author":"Yang","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2024.167648_bb0510","article-title":"Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease","volume":"7","author":"Privitera","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.bbadis.2024.167648_bb0515","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2468-1253(22)00307-7","article-title":"Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study","volume":"8","author":"Atia","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0520","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0525","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPG.0000000000002362","article-title":"Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center","volume":"69","author":"Dayan","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"10.1016\/j.bbadis.2024.167648_bb0530","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/MIB.0000000000000865","article-title":"Multi-center experience of Vedolizumab effectiveness in pediatric inflammatory bowel disease","volume":"22","author":"Singh","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.bbadis.2024.167648_bb0535","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11072004","article-title":"Dual biologic therapy for the treatment of pediatric inflammatory bowel disease: a review of the literature","volume":"11","author":"Wlazlo","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bbadis.2024.167648_bb0540","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","article-title":"Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development","volume":"155","author":"Matro","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bbadis.2024.167648_bb0545","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cgh.2017.08.041","article-title":"Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines","volume":"16","author":"Beaulieu","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bbadis.2024.167648_bb0550","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","article-title":"The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease","volume":"9","author":"van der Woude","year":"2015","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.bbadis.2024.167648_bb0555","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/gutjnl-2014-307127","article-title":"Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results","volume":"64","author":"Wyant","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.bbadis.2024.167648_bb0560","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40265-017-0693-5","article-title":"Incidence, prevention and management of anti-drug antibodies against therapeutic antibodies in inflammatory bowel disease: a practical overview","volume":"77","author":"Hindryckx","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bbadis.2024.167648_bb0565","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000358135","article-title":"Have biologics changed the natural history of Crohn\u2019s disease?","volume":"32","author":"Mandel","year":"2014","journal-title":"Dig. Dis."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443924006422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443924006422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:18:09Z","timestamp":1772457489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443924006422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":113,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0925443924006422"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2024.167648","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological agents as attractive targets for inflammatory bowel disease therapeutics","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2024.167648","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"167648"}}